Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Blood
Main Authors: Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Formáid: Artigo
Teanga:Inglês
Foilsithe: American Society of Hematology 2014
Ábhair:
Clinical Trials and Observations
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468583/
https://ncbi.nlm.nih.gov/pubmed/24904120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548941
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla